ArticleCalcified tissue international2026
Dissecting Immune Mechanisms Underlying Sarcopenia Using Multi-omics Approaches.
Article in Calcified tissue international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Sarcopenia is an age-related muscle disease, and its gene regulation in immune cells is not well understood. Using immune cell-specific single-cell expression quantitative trait loci (sc-eQTLs), genome-wide association studies (GWAS), and multi-omics data, we systematically explored their potential causal roles in sarcopenia. We integrated sc-eQTL and cis-eQTL data from whole blood and skeletal muscle, seven sarcopenia-related phenotypes GWAS summary statistics, and used a Muscle Function-Mass Genetic Structural Equation Model (MF-M GSEM), Mendelian randomization (MR), and Bayesian colocalization analyses to assess causal gene effects across 14 immune cell types, whole blood, and skeletal muscle. A two-step MR was then applied to explore mediation through common diseases and carnitine-related metabolites. Fourteen genes, including HLA-DRB1, HLA-C, and SLC22A5, showed significant causal effects on at least three sarcopenia phenotypes in one or more immune cell types (Bonferroni-adjusted P < 0.05; posterior probability for hypothesis 4 > 0.8). Heart failure, rheumatoid arthritis, and chronic kidney disease mediated the causal effects of sc-eQTLs for FNBP4, HLA-DRB1, HLA-C, and HLA-DQA1 on MF-M GSEM (P < 0.05). Isovalerylcarnitine (C5) mediated the causal effect of the cis-eQTL of SLC22A5 in skeletal muscle on MF-M GSEM, with a mediation proportion of 67.6% (FDR-adjusted P < 0.05). Our findings highlight that immune cell-specific expression of HLA-DRB1, HLA-C, SLC22A5, and FNBP4 contributes to the pathogenesis of sarcopenia, suggesting these genes as potential therapeutic targets and mechanistic entry points for future research.
Indexed as
Identifiers
42068367What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.